Zydus Lifesciences has informed that it enclosed a copy of press release dated December 19, 2024, titled ‘Zydus receives final approval from USFDA for Lidocaine and Prilocaine Cream USP, 2.5%/2.5%.’
The above information is a part of company’s filings submitted to BSE.